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SUSCEPTIBILITY TO ANTIBIOTICS IN URINARY TRACT INFECTIONS IN A  
SECONDARY CARE SETTING FROM 2005-2006 AND 2010-2011, IN SÃO PAULO, BRAZIL:  
DATA FROM 11,943 URINE CULTURES
Érique José PEIXOTO DE MIRANDA(1), Gerson Sobrinho SALVADOR DE OLIVEIRA(1), Felício Lopes ROQUE(2),  
Sílvia Regina DOS SANTOS(3), Rodrigo Diaz OLMOS(4) & Paulo Andrade LOTUFO(5)
SUMMARY
Introduction: Urinary tract infection (UTI) has a high incidence and recurrence, therefore, treatment is empirical in the 
majority of cases. Objectives: The aim of this study was to analyze the urine cultures performed at a secondary hospital, during two 
periods, 2005-2006 and 2010-2011, and to estimate the microbial resistance. Patients and methods: We analyzed 11,943 aerobic 
urine cultures according to basic demographic data and susceptibility to antibiotics in accordance with the Clinical and Laboratory 
Standards Institute (CLSI) for Vitek 1 and 2. Results: Most of our cohort consisted of young adult females that were seen at the 
Emergency Department. E. coli was the most frequent (70.2%) among the 75 species isolated. Resistance of all isolates was ≥ 20% 
for trimethoprim/sulfamethoxazole (TMP/SMX), norfloxacin, nitrofurantoin, cefazolin and nalidixic acid. Although E. coli was more 
susceptible (resistance ≥ 20% for TMP/SMX and nalidixic acid) among all of the isolates, when classified by the number and percentage 
of antibiotic resistance. Global resistance to fluoroquinolones was approximately 12%. Risk factors for E. coli were female gender 
and an age less than 65 years. Men and patients older than 65 years of age, presented more resistant isolates. Extended spectrum 
beta-lactamases (ESBL) were identified in 173 out of 5,722 Gram-negative isolates (3.0%) between 2010 and 2011. Conclusion: E. 
coli was the most frequent microbe isolated in the urine cultures analyzed in this study. There was a significant evolution of bacterial 
resistance between the two periods studied. In particular, the rise of bacterial resistance to fluoroquinolones was concerning.
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INTRODUCTION
Urinary tract infection (UTI) is one of the most common infections 
diagnosed in patients, ranking first in the United States of America 
(USA). UTIs are characterized by high incidence, high recurrence and a 
mild severity of evolution in most cases. Because of the uncomfortable 
symptoms they cause, they often force physicians to introduce antibiotic 
treatment prior to obtaining the culture results14,15. The resolution 
of between 25% and 42% of cystitis UTIs in the placebo arms of 
randomized controlled trials, with little incidence of evolution to 
complicated infections and a proportion of one case of pyelonefritis per 
every 28 cases of cystitis, confirms the mild character of UTIs15. Current 
guidelines establish that lower UTIs in young women should be treated 
empirically with short-term antibiotics. Therefore, it is important that 
the antimicrobial susceptibility data of major uropathogens are known. 
In particular, given that it is an infection that is most often treated 
empirically, data on major uropathogens should be systematically 
and regularly analyzed. However, in Brazil, there is a paucity of 
such data.
Despite the guidelines, requests for urinalysis and microscopic 
examination of urine (pyuria, leukocyte esterase, nitrite, and the 
presence of bacteria) as well as requests for urine culture for diagnosis 
of uncomplicated UTIs, is common among physicians in Brazil14,23. 
As a result, many cases that should be treated in a primary setting care 
are unnecessarily referred to the emergency department of secondary 
hospitals, resulting in increased health care costs. In clinical practice, 
physicians and their patients commonly insist that urine tests are 
necessary for the diagnosis of uncomplicated UTIs. The greatest proof 
of these assertions is evident from retrospective studies in several 
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regions of Brazil, which were only possible because of this “breach of 
protocol”2,4,5,9,10,19,20,22,24,25,26.
We hypothesized that, in recent years in our environment, the 
microbiological profile of isolated uropathogens has become increasingly 
worse. Recent literature15 postulates a fluoroquinolone sparing protocol; 
however, if more than 20% of uropathogens are resistant to a drug, 
it cannot be used empirically. Therefore, the aim of this study is to 
retrospectively analyze the bacterial susceptibility data of uropathogens 
isolated from patients at a university community hospital in the last 
decade and to establish a new treatment protocol in this healthcare setting.
MATERIALS AND METHODS
The University Hospital of São Paulo is a 246-bed secondary care 
setting, one of the teaching hospitals of the University of São Paulo 
School of Medicine, and serves a population of approximately 500,000 
inhabitants in the western area of the city of São Paulo. The hospital 
Emergency Department serves approximately 800 patients a day. 
This is a retrospective study, which included positive urine cultures 
from patients who were collected during the periods from 2005 to 2006 
and from 2010 and 2011, at the University Hospital in the Emergency 
Department, Outpatient Clinics, and from external patients. The aim of 
the study was to compare resistance to antimicrobial agents during two 
time periods, regardless of whether more than one urine culture per patient 
was collected during those time periods. The samples were processed 
and analyzed at the Section of Microbiology of the Clinical Laboratory 
of the University Hospital.
Only aerobic bacterial infections were analyzed in this study. 
Anaerobic bacterial infection, fungal infection and negative cultures 
were excluded from this study. Positive urine cultures were obtained 
by consulting Apolo software (Oracle Corporation, Redwood City, 
California, USA), without consulting the medical records of the patients, 
except for information about patients with urine culture with count < 
100,000 colony forming units (CFU) per milliliter of urine.
Urine collected by all methods during these time periods was 
included, although the standardized laboratory method is to collect the 
specimen urine midstream.
Urine cultures were taken quantitatively distributed on blood agar 
and MacConkey agar plates with a calibrated loop with a volume of 
10 µL (references 35095 and 35092, respectively, bioMérieux, Rio de 
Janeiro, Brazil). CPS ID2 chromogenic agar (bioMérieux, Rio de Janeiro, 
Brazil) has been used in the laboratory since 2012. Urine cultures with a 
count ≥ 100,000 colony forming units (CFU) per milliliter of urine were 
considered positive after incubation in a bacteriologic incubator at 35 
°C for at least 24 hours27. This study also included as positive counts > 
1,000 CFU and < 100,000 CFU of less than or equal to two infectious 
agents isolated (only pure or mixed culture) in the analysis because the 
patients presented symptoms of a UTI, which was documented in their 
chart16. Only one the most significant germs isolated between two agents 
from each agar plate was considered in the analysis.
Identification of bacterial species and an antibiogram was performed 
by Vitek 1 (from 2005 to 2006) and by Vitek 2 (from 2010 to 2011) 
(bioMérieux, St. Louis, Missouri, USA). Card N104 was used in Vitek 2. 
Detection of extended spectrum beta-lactamases (ESBL) was performed 
on the samples from 2010 to 2011 by Vitek 2.
The standardization of the antibiogram followed the standards and 
recommendations of the Clinical and Laboratory Standards Institute 
(CLSI), documents M100-S15 (2005)5, M100-S16 (2006)6, M100-S20 
(2010)7 and M100-S21 (2011)8. Antibiograms of nonfermenting Gram-
negative agents were confirmed by the E-test® (AB Biodisk, Solna, 
Sweden) and/or Kirby-Bauer disk diffusion18 methods, according to 
the same standards. No value of the minimum inhibitory concentration 
was computed in the analysis due to the lack of reliability of the 
automated antibiogram, especially the values obtained by Vitek 1. ATCC 
(American Type Culture Collection) strains of Escherichia coli (ATCC 
25922), Klebsiella pneumoniae ESBL (ATCC 700063), Klebsiella 
pneumoniae (ATCC 700603), Pseudomonas aeruginosa (ATCC 27853) 
and Shigella sonnei (ATCC 25931) were used for quality control of 
Vitek analysis. For analysis purposes, we considered the frequency 
of susceptibility rather than resistance, which is different from most 
studies in the literature because the semiquantitative antibiogram also 
measures intermediate susceptibility. For the purposes of the analysis, 
intermediate susceptibility was included as resistance, as occurs in 
clinical practice.
A review of the literature was performed in MEDLINE with the terms 
“outpatient UTI” and “resistance to antibiotics” and “Brazil”, as well as 
LILACS and SciELO (Scientific Electronic Library Online), which are 
Latin American scientific databases.
ETHICS
This study was approved by the Research Ethics Committee 
(Advisory Board) of the University Hospital of the University of São 
Paulo.
STATISTICAL ANALYSIS
Demographic data (sex, age and setting of the healthcare entrance 
at the hospital) and periods were submitted to exploratory data analysis 
and the assumption of normality. Numerical data were presented as the 
medians and interquartile ranges (IQR: Q1 and Q3) because the data 
were non-normal. Categorical data (sex, setting and susceptibility to 
antibiotics) were presented as the number and percentage. The Mann-
Whitney U test was used for comparison of numerical non-normal 
variables. The Pearson uncorrected chi-square (c²) or Fisher’s exact 
tests were used for comparison of susceptibility between the two periods 
(2005-2006 vs. 2010-2011). A crude (unadjusted or univariate) odds 
ratio, 95% confidence interval and p-value were used to assess risk 
factors for infection by the most frequently isolated bacteria. All tests 
were two-sided. Statistical significance was considered at p < 0.05. 
Statistical analysis was performed using the statistical software SPSS 
10.0 for Windows (IBM, Chicago, IL, USA).
RESULTS
In both periods analyzed, 11,943 aerobic urine cultures were obtained, 
5,755 (48.2%) from the period between 2005 and 2006 and 6,188 
(51.8%) from the period between 2010 and 2011. This is an average of 
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7.88 positive urine cultures per day during the first period and 8.40 in 
the second. Only 849 (7.1%) cultures presented counts less than 100,000 
UFC in the first period (2005-2006).
The median age of patients was 36 years old (IQR: 20-65 years), 
ranging from zero to 100 years of age. There was a statistically significant 
difference between the median age of men and women in the study: 57.5 
years old (IQR: 14.25-76 years) vs. 32 years old (IQR: 21-59 years), 
respectively; p < 0.0001.
By age group, among patients 0 to 14 years old, the frequency of 
positive urine cultures was 2,007 (16.8%); 15 to 64 years, 6,834 (57.2%); 
and ≥ 65 years, 3,102 (26.0%). The female-to-male ratio per age strata 
was the following: 0.73 (206/283) for < 2 years old; 3.60 (267/74) for 
≥ 2-5 years; 5.20 (229/44) for >5-14 years; 6.25 (2,794/447) for ≥14-64 
years; and 1.64 (877/534) for > 65 years (p < 0.0001, Pearson chi-square).
The frequency of females was 77.6%, with females between the ages 
of 14 and 64 representing 23.4% of the total. Among the patients studied, 
the majority of samples were collected in the Emergency Department, 
8,931 (74.8%). Other samples, 1,944 (16.3%), were collected from the 
outpatient Clinic, and others, 1,059 (8.9%), were considered “external” 
(patients from primary care units in the western region of São Paulo).
It was not possible to calculate the positivity rate of the urine 
cultures. Of all of the isolates, 10,891 (91%) were Gram-negative, of 
which, 10,704 were Enterobacteriaceae (98.3%) and 187 (1.7%) were 
nonfermenting Gram-negative bacteria (manly Pseudomonas aeruginosa, 
132; Acinetobacter baumannii, 36; and Stenotrophomonas maltophilia, 
7). Seventy-five different bacterial species were isolated from the 
urine cultures (Table 1), but the most frequently observed species were 
Escherichia coli (8,376, 70.2%). The order of frequency of bacteria was 
statistically significant and varied between men and women (p < 0.0001) 
(Table 2).
The main risk factor for E. coli and Staphylococcus saprophyticus 
infection was female sex (Table 2) [crude odds ratio (OR) = 3.60, 95% 
CI (confidence interval): 3.30 to 3.90; p < 0.0001 and OR = 10.37, 95% 
CI: 3.84-28.0; p < 0.0001, respectively]. Both bacteria were also more 
common in younger patients. E. coli was more common in patients less 
than 65 years old [(OR) = 1.98 (95% CI: 1.81 to 2.16); p = 0.033], and 
S. saprophyticus was more prevalent in patients aged 14 to 65 years 
[OR = 8.62 (95% CI: 4.77-15.58); p < 0.0001]. For Proteus mirabilis, the 
main risk factor was male sex, even though an age of less than 65 years 
(OR = 1.20, 95% CI: 1.01 to 1.44; p = 0.033) was also a risk factor. In 
the stratum of ages 0-14, we observed the largest male-to-female ratio 
(1.7), whereas in the 15-64 year stratum it was 0.15, and in the older age 
stratum (≥ 65 years) it was 0.61.
Male sex was also a risk factor for the following less frequent 
bacteria: Klebsiella pneumoniae, Enterococcus faecalis, Enterobacter 
aerogenes, P. aeruginosa, Enterobacter cloacae, Citrobacter freundii and 
Morganella morganii (Table 2). The crosstabulation between stratum of 
age and gender resulted in a male-to-female rate in the age range of 65 
years or greater divided per bacteria: 0.32 (E. coli), 1.023 (E. faecalis), 
1.65 (E. cloacae), 1.625 (C. freundii), 3.25 (Staphylococcus epidermidis), 
1.81 (Klebsiella oxytoca), 2.22 (E. aerogenes), 2.26 (S. aureus), and 
1.875 (Citrobacter koseri).
Extended spectrum beta-lactamases (ESBL) were identified in 
173 of the 5,722 Gram-negative isolates (3.0%) that were collected 
between 2010 and 2011 and analyzed by the Vitek 2. Of these, 108 were 
Table 1
Frequency of species among 11,943 bacteria isolated from urine cultures 
collected between 2005-2006, and 2010- 2011 at the University Hospital of the 
University of São Paulo (HU-USP)
Order Bacteria isolated in urine culture Frequency (n) 
Percentage 
(%)
1º Escherichia coli 8,376 70.2%
2º Proteus mirabilis 795 6.8%
3º Klebsiella pneumoniae 692 5.9%
4º Enterococcus faecalis 322 2.8%
5º Enterobacter aerogenes 187 1.7%
6º Staphylococcus saprophyticus 148 1.2%
7º Pseudomonas aeruginosa 132 1.1%
8º Enterobacter cloacae 126 1.1%
9º Citrobacter freundii 122 1.0%
10º Morganella morganii 104 0.9%
11º Staphylococcus aureus 98 0.8%
12º Staphylococcus epidermidis 85 0.7%
13º Citrobacter koseri 82 0.7%
14º Staphylococcus sp. DNAse 
negative
65 0.5%
15º Staphylococcus warneri 62 0.5%
16º Serratia marcescens 62 0.5%
17º Klebsiella oxytoca 58 0.5%
18º Streptococcus agalactiae 43 0.4%
19º Staphylococcus hominis 38 0.3%
20º Acinetobacter baumannii 36 0.3%
21º Others 310 2.1%
Total 11,943 100.0%
Notes: 1: neg.: negative, or Staphylococcus spp., neither classified as S. aureus 
(DNAse positive) nor had a specie discrimination, due to lack of discriminatory 
power by automated method (Vitek 1 or 2).
Appendix: Another isolates, in order of frequency, from the twenty-first: 
Staphylococcus haemolyticus, Enterococcus faecium, Streptococcus viridans, 
Streptococcus mitis, Proteus vulgaris, Staphylococcus simulans, Providencia 
stuartii, Providencia rettgeri, Staphylococcus sciuri, Salmonella spp., 
Stenotrophomonas maltophilia, Staphylococcus auricularis, Staphylococcus 
capitis, Citrobacter amalonaticus, Proteus penneri, Raoultella ornithinolytica, 
Raoultella planticola, Staphylococcus xylosus, Enterobacter asburiae, 
Enterococcus spp., Serratia fonticola, Serratia liquefaciens, Streptococcus 
anginosus, Streptococcus sanguinis, Aeromonas spp., Gram-negative (not 
discriminated), Burkholderia cepacia, Citrobacter braakii, Citrobacter spp., 
Enterobacter gergoviae, Enterobacter spp., Pseudomonas spp., coagulase-
negative Staphylococcus spp., Staphylococcus intermedius, Staphylococcus lentus, 
Staphylococcus lugdunensis, Streptococcus bovis, Streptococcus spp. gallolyticus 
var. gallolyticus, Acinetobacter haemolyticus, Acinetobacter lwoffii, Acinetobacter 
spp., nonfermenting Gram-negative bacteria, Enterobacter sakazaki, Enterococcus 
hirae, Klebsiella ornithinolytica, Pantoea spp., Proteus spp., Providencia spp., 
Pseudomonas fluorescens, Pseudomonas putida, Staphylococcus cohnii spp. 
cohnii, Streptococcus gordonii, Streptococcus parasanguinis, Streptococcus 
pyogenes, beta-hemolytic group G Streptococcus spp.
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Escherichia coli (1.3% of total per specie), 59 were K. pneumoniae 
(8.5%), four were K. oxytoca (6.9%), and two were P. mirabilis (0.25%). 
Of these, 4.6% (n = 8) of patients were 0-14 years old; 38.7% (n = 67) 
were 15-64 years; 56.7% (n = 98) were ≥ 65 years old; 60.1% (n = 104) 
were female; and 74% (n = 128) were from the Emergency Department. 
Of the patients ≥ 65 years old, 55.1% were female and 44.9% were male.
Although it was neither carried out using the Hodge test nor another 
method for detecting carbapenemases, including KPC (K. pneumoniae 
carbapenemase), the susceptibility to ertapenem was high among 
isolates of Enterobacteriaceae (E. coli, 100%; Proteus mirabilis, 99.5%; 
K. pneumoniae, 98.5%; and E. aerogenes, 100%) during the period 
between 2010 and 2011. Global analysis of the isolates demonstrated 
a susceptibility of 99.8% to ertapenem (2010-2011). Susceptibility 
to vancomycin among isolates of E. faecalis was 98.6% and 97.3% 
(p = 0.699), in the 2005-2006 and 2010-2011 periods, respectively.
SUSCEPTIBILITY
In an attempt to select an appropriate antibiotic for empirical 
treatment, we performed a comprehensive analysis of the antibiograms 
of 11,943 isolates from urine cultures from the two periods studied, 
despite differences in interpretation of susceptibility, particularly among 
Gram-positive and Gram-negative bacteria. Global susceptibility was 
83.4% (67,864 out of 81,406), in 2005-2006 vs. 83.5% (72,442 out 
of 86,770) in 2010-2011, p = 0.499. Only clindamycin, cefazolin, 
erythromycin, gentamicin (high level resistance, tested for Enterococcus 
spp. infection), linezolid, penicillin G (parenteral), tetracycline and 
vancomycin had no statistically significant differences in antimicrobial 
susceptibility in both periods. All of these antimicrobial agents are used 
for covering Gram-positive bacterial infections. All of the following 
antimicrobial agents were highly statistically significant different in the 
two periods (p < 0.0001): nalidixic acid (88.7 vs. 78.1), amikacin (98.4 
vs. 99.5), amoxicillin/clavulanate (98.4 vs. 99.5), ampicillin/sulbactam 
(21.9 vs. 43.6), cephalothin (77.9 vs. 64.7), cefepime (98.0 vs. 95.4), 
ceftriaxone (98.2 vs. 95.9), ciprofloxacin (90.1 vs. 83.4), gentamicin 
(94.4 vs. 93.3), imipenem (99.8 vs. 93.1), meropenem (89.0 vs. 99.8), 
nitrofurantoin (86.4 vs. 77.4), norfloxacin (91.3 vs. 75.6) and piperacillin/
tazobactam (72.9 vs. 94.4). The difference was minor in the following 
cases: ampicillin (45.1 vs. 44.0, p = 0.037), aztreonam 57 (48.3 vs. 
61.5, p = 0.048), cefuroxime axetil (92.1 vs. 86.9, p = 0.004), oxacillin 
(22.4 vs. 35.6, p = 0.001), rifampin (96.4 vs. 97.7, p = 0.002) and 
trimethoprim/sulfamethoxazole (TMP/SMX) (68.0 vs. 65.9, p = 0.035). 
Global resistance to fluoroquinolones (levofloxacin, norfloxacin and 
ciprofloxacin) was 12%.
Among E. coli, the most commonly isolated agent, only TMP/SMX 
and nalidixic acid showed a resistance rate of ≥ 20%, in the period from 
2010 to 2011. The global susceptibility was 88.3% (50,142/56,764) 
vs. 86.1% (55,436/64,400); p < 0.0001. Among P. mirabilis, except for 
colistin and nitrofurantoin, which were antibiotics against which this 
species has intrinsic resistance (0% susceptibility in this study) and TMP/
SMX (susceptibility of 77.8% and 74.5% in the first and second periods, 
respectively), all other antibiotics had < 20% resistance in both periods. 
K. pneumoniae had a global susceptibility of 80.8% (3,242/4,013) vs. 
76.8% (4,719/6,150); p < 0.0001. Various antibiotics showed a resistance 
rate higher than 20%, but norfloxacin was a good option in both periods 
that were studied (89.7% vs. 82.6%). Among E. faecalis, the global 
susceptibility was 77.2% (880/1,141) vs. 82.2% (1,328/1,616); p = 0.001, 
which indicated an improvement in susceptibility during the two periods.
The most resistant species was E. aerogenes, with a global 
susceptibility of 70.9% (878/1,237) vs. 68.9% (1,012/1,468); p = 0.674. 
In contrast to the aforementioned bacteria, S. saprophyticus presented 
a favorable profile with an improvement in global susceptibility during 
the two periods, 61.1% (1,249/2,043) vs. 88.2% (15/17); p = 0.042. The 
reason that the number of samples that were obtained during the second 
period was small is because the laboratory is no longer disclosing the 
antibiogram for S. saprophyticus, as recommended by the CLSI. Among 
P. aeruginosa, the global susceptibility was 48.3% (532/1,102) in 2005-
2006 vs. 85.6% (640/748) in 2010-2011; p < 0.0001.
The global frequency of intermediate susceptibility was the 
following: 1.7% (2005-2006) and 2.7% (2010-2011) (global); 1.6% 
Table 2
Frequency by gender of species among 11,943 bacteria isolated from urine cultures collected between 2005-2006, and 2010- 2011 at the  
University Hospital of the University of São Paulo (HU-USP)
Order Male, n = 2,673 Female, n = 9,270 Odds ratio* CI 95% p
1º Escherichia coli, 1,271 (47.5% ) Escherichia coli, 7,103 (76.6%) 3.60 (F) 3.30-3.90 <0.0001
2º Proteus mirabilis, 302 (11.3%). Proteus mirabilis, 493 (5.31%) 2.27 (M) 1.94-2.64 <0.0001
3º Klebsiella pneumoniae, 215 (8.04%) Klebsiella pneumoniae, 477 (5.1%) 1.61 (M) 1.36-1.91 <0.0001
4º Enterococcus faecalis, 151 (5.65%) Enterococcus faecalis, 171 (1.8%) 3.19 (M) 2.53-4.01 <0.0001
5º Morganella morganni, 77 (2.88%) Staphylococcus saprophyticus, 144 (1.5%) – – –
6º Pseudomonas aeruginosa, 76 (2.84%) Enterobacter aerogenes, 131 (1.4%) – – –
7º Enterobacter cloacae, 59 (2.20%) Enterobacter cloacae, 67 (0.72%) 3.09 (M) 2.17-4.41 <0.0001
8º Citrobacter freundii, 56 (2.10%) Citrobacter freundii, 66 (0.71%) 2.98 (M) 2.08-4.27 <0.0001
9º Enterobacter aerogenes, 56 (2.10%) Staphylococcus warneri, 59 (0.63%) – – –
10º Staphylococcus aureus, 52 (1.94%) Pseudomonas aeruginosa, 56 (0.60%) – – –
Notes: *(F): female, reference is male; (M): male, reference is female (reference is the counterpart of the gender indicated in parentheses). Morganella morganni: 
OR = 10.15 (95% CI: 6.53-15.76), p < 0.0001 (male); Pseudomonas aeruginosa: OR = 4.81 (95% CI: 3.40-6.82), p < 0.0001 (male); Staphylococcus saprophyticus: 
OR = 10.37 (95% CI: 3.84-28.0), p < 0.0001 (female); Enterobacter aerogenes: OR = 1.48 (95% CI: 1.08-2.02), p = 0.012 (male).
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and 2.7% (E. coli); 0.8% and 2.5% (Proteus mirabilis); 3.0% and 3.5% 
(K. pneumoniae); 0.5% and 2.0% (E. faecalis); 3.6% and 3.7% (E. 
aerogenes); 0.5% and 0% (S. saprophyticus); and 4.6% and 5.3% (P. 
aeruginosa).
The comparison among the age strata, 0-14, 15-64 and ≥ 65 years 
old, versus gender, among the 45 antibiotics that were tested (Table 
4), showed statistically significant differences for 25 of the antibiotics 
between males and females, with greater rates of resistance in men and 
in patients older than 65 years. The antibiotics demonstrating these 
differences were the following: nalidixic acid, amikacin, amoxicillin/
clavulanate, ampicillin, ampicillin/sulbactam, aztreonam, cephalothin, 
cefazolin, cefepime, cefotaxime, ceftazidime, ceftriaxone, cefuroxime 
axetil, ciprofloxacin, carbenicillin, ertapenem, streptomycin (high 
level resistance), gentamicin, imipenem, meropenem, nitrofurantoin, 
piperacillin/tazobactam, ticarcillin, TMP/SMX and vancomycin.
DISCUSSION
This is the third largest study of susceptibility to antibiotics in urinary 
tract infections in Brazil (Table 5). All studies of this type in Brazil, except 
for one10, are retrospective and exclude many demographic variables, 
except gender and age, as well as clinical, radiological or laboratory 
variables, which does not allow multivariate analysis, and thus, greatly 
reduces the impact of these publications1,2,4,9,19,20,25,26.
Initially, this study had the goal of guiding the implementation of 
a protocol for the treatment of UTIs; however, the lack of clinical data 
(mainly regarding the uncomplicated infections) and the large number 
of isolates, preclude such an achievement.
Considering that $5.30 US dollars was paid for each urine culture and 
antibiogram according to the table of Brazilian Unified Health System, the 
“estimated cost” of this study was $63,297.9027. Taking into account that 
in the same period approximately 60,000 urine cultures were requested, 
of which, only 20% were positive, the total cost to the health system was 
about $183,000.00 just in the University Hospital of the University of 
São Paulo, which is one of 6,753 hospitals in Brazil, of which only 30% 
are public. This justifies conducting a prospective study to address the 
clinical characteristics of patients in Brazil.
The biggest (multicenter) impact study involving Brazilian cases 
of UTI isolates was the SENTRY13, which was published a decade ago 
and involved four centers in the country but only included inpatients. 
The methodology included the use of the gold standard procedure of 
microdilution for the preparation of the antibiograms and involved 
1,961 urine isolates. E. coli was the most frequent pathogen that was 
isolated followed by Klebsiella spp., P. aeruginosa, and P. mirabilis. 
At that time, the amount of detected resistance was > 45% to TMP/
SMX and a resistance to fluoroquinolones of 17.5-18.9% was detected. 
Furthermore, the susceptibility to broad-spectrum antibiotics (91.0-
100.0%) and nitrofurantoin (87%) remained high, including piperacillin/
tazobactam, aztreonam, extended-spectrum cephalosporins (third and 
fourth generations), carbapenems and amikacin. At that time, the biggest 
problems in terms of resistance was carbapenem-resistant P. aeruginosa, 
ciprofloxacin-resistant E. coli and ESBL-producing K. pneumoniae. The 
Enterobacteriaecae producing carbapenemases were not even mentioned 
in that study13.
The data found in this study are similar to those found in previous 
literature, with some minor peculiarities. The proportion of females 
(77.6% vs. 69%-88.8% in studies), the female-to-male ratio by age group, 
the age group most affected (15-64 years: 57.2%) and the first isolated 
agent (E. coli, 70.2%) and frequency is very similar to that found in many 
published studies2,4,9,10,15,19,20,25,26. The percentage of E. coli that is isolated 
from UTIs, according to international literature, is 75% to 95%15. In 
Brazil, the frequency varied from 48.2%9 to 71.6%19 in São Paulo. The 
proportion of Gram-negative isolates varied from 84.4% to 87.3%4,19,24.
The second most frequent agent presented a variation in different 
studies in Brazil. Except in studies by COSTA et al.9 and KOCH 
et al.20, in which Proteus mirabilis was the second most frequently 
isolated uropathogen, the second most commonly isolated pathogen was 
Enterococcus spp.25, K. oxytoca and S. agalactiae22, Enterobacter spp.2, 
and K. pneumoniae4,11,19,22.
In the one Brazilian study to date11 about ESBL-producing 
Enterobacteriaceae in community-acquired UTIs, which evaluated 
78,964 urine cultures in Juiz de Fora, State of Minas Gerais, Southeastern 
of Brazil, from 2001 to 2009, detected a frequency of 0.66% (n = 512) 
over nine years in the majority of patients older than 65 years (female, 
52.6% and male, 48.1%), which is similarly to the results of this study. 
The percentage reported in the literature varied from 0.2% to 3.5%11, 
which is close to the value of 3.0% among Gram-negative tested between 
2010 and 2011, in this study. Although the most frequently isolated 
bacterium that produces ESBL is Klebsiella spp. (24 to 60%), DIAS et 
al. also detected E. coli (72.4%), followed by Klebsiella spp. (19.8%), 
which is similar to this study in which E. coli (62.4%), Klebsiella spp. 
(36.4%) and Proteus spp. (1.2%) were isolated. This study did not perform 
a confirmatory test for ESBL, which can result in false positives12.
Global resistance was ≥ 20% for TMP/SMX, tetracycline, 
norfloxacin, nitrofurantoin, erythromycin, cefazolin and nalidixic acid, 
especially leveraged by other bacteria than E. coli. Global resistance 
was ≥ 20% for TMP/SMX, tetracycline, norfloxacin, nitrofurantoin, 
erythromycin, cefazolin and nalidixic acid in the isolated bacteria 
other than E. coli. There was significant difference between virtually 
all antibiotics in the two periods studied, which was commonly highly 
significant (p < 0.0001); however, no difference was observed between 
the antibiotics used for coverage of Gram-positive bacteria, except for 
rifampin and oxacillin. The fact that there was no statistically significant 
difference between the two periods in the overall susceptibility to key 
antibiotics by Gram-positive bacteria reveals the minor importance of 
these bacteria in the pathogenesis of UTIs in the study population, due to 
the reduced presence of selective pressure, which occurs with antibiotics 
that are used to treat Gram-negative bacteria.
The study by KOCH et al.20 assessed the temporal trends of 
antimicrobial resistance, from 2000 to 2004 of gentamicin (p = 0.98), 
cephalothin (p = 0.29), cefoxitin (p = 0.16), TMP/SMX (p = 0.40), 
nalidixic acid (p = 0.02), ceftriaxone (p = 0.12) and ciprofloxacin 
(p = 0.07). Therefore, unlike this study, only nalidixic acid had statistical 
significance and ciprofloxacin had a statistical trend, which demonstrates 
the selective pressure that was exerted by quinolones in Rio Grande do 
Sul, southern Brazil. The same study also showed that older patients 
showed increased resistance to nalidixic acid, ciprofloxacin and 
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Table 4
Susceptibility to antibiotics of all 11,943 bacteria isolated from urine cultures, between 2005 and 2006, and 2010 and 2011 at the University Hospital of the 
University of São Paulo (HU-USP), stratified by gender and stratum of age
Antibiotic, susceptible, n(%) Male gender  Female gender0-14 years 15-64 years ≥65 years 0-14 years 15-64 years ≥65 years
Nalidixic acid 603 (97.3)* 532 (74.2)* 506 (59.3)* 1.198 (94.1)* 4.794 (88.1)* 1.220 (69.8)*
Amikacin 528 (100) 635 (96.1)* 794 (95.0)* 1.107 (100) 4.740 (99.8)* 1.569 (99.2)*
Amoxicillin/clavulanate 454 (73.2)* 490 (68.3)* 530 (62.1)* 1.050 (82.5)* 4.637 (85.2)* 1.395 (79.8)*
Ampicillin 253 (38.8) 304 (37.7)* 318 (31.3)* 539 (41.2) 2.802 (48.6)* 880 (46.5)*
Ampicillin/sulbactam 3 (16.7) 17 (29.8)* 40 (44.9)* 2 (11.1) 39 (17.1)* 14 (23.3)*
Aztreonam 9 (100) 25 (49.0) 31 (41.9)* 18 (85.7) 11 (45.8) 27 (64.3)*
Cephalothin 457 (73.2)* 448 (60.3)* 443 (49.4)* 964 (75.4)* 4.154 (76.2)* 1.185 (66.9)*
Cefazolin 87 (77.0)* 102 (68.5)* 106 (70.7)* 178 (87.7)* 741 (73.0)* 217 (83.8)*
Cefepime 527 (99.8) 604 (91.4)* 725 (86.5)* 1.095 (98.9)* 4.692 (98.7)* 1.499 (94.8)*
Cefotaxime 230 (95.0) 296 (81.8)* 374 (73.3)* 549 (95.8) 2.717 (97.2)* 854 (88.5)*
Cefoxitin 0 4 (14.8)* 3 (6.8) 5 (45.5) 17 (65.4)* 4 (16.0)
Ceftazidime 254 (98.8) 349 (87.5)* 444 (81.0)* 609 (97.9) 2.902 (97.7)* 1.383 (87.7)*
Ceftriaxone 383 (98.7)* 374 (91.9)* 382 (91.0)* 705 (100)* 2.677 (99.5)* 807 (97.6)*
Cefuroxime axetil 272 (93.2)* 243 (77.9)* 227 (70.7)* 528 (97.8)* 1.954 (96.1)* 557 (88.8)*
Ciprofloxacin 657 (98.8) 641 (76.2)* 692 (63.0)* 1.308 (98.2) 5.519 (92.5)* 1.446 (74.7)*
Clindamycin 12 (100) 21 (63.6)* 41 (75.9) 14 (100) 263 (98.9)* 25 (58.1)
Chloramphenicol – – 1 (100) – 2 (100) –
Carbenicillin 32 (37.6) 52 (61.9) 32 (45.7)* 59 (39.6) 306 (55.8) 97 (60.2)*
Colistin – 3 (75.0) 2 (100) 1 (100) 4 (80.0) 4 (100)
Erythromycin 9 (75.0) 16 (48.5)* 31 (57.4) 13 (86.7) 216 (81.2)* 23 (53.5)
Ertapenem 231 (100) 318 (99.4) 446 (98.9)* 563 (100) 2778 (99.9) 933 (99.9)*
Streptomycin 7 (58.3) 10 (62.5) 38 (73.1) 5 (55.6) 14 (63.6) 30 (62.5)
Streptomycin (high level resistance) 10 (83.3) 15 (57.7) 39 (76.5)* 8 (100) 35 (72.9) 18 (34.0)*
Gentamicin 623 (97.0) 702 (86.8)* 855 (84.5)* 1.271 (96.6) 5.617 (96.4)* 1.680 (91.0)*
Gentamicin (high level resistance) 21 (87.5) 27 (64.3)* 80 (77.7) 17 (100) 64 (91.4)* 70 (70.0)
Imipenem 296 (100) 338 (98.5)* 383 (98.0)* 545 (100) 1.975 (100)* 646 (99.5)*
Levofloxacin – – – – 7 (100) 3 (100)
Linezolid 24 (100) 55 (100) 117 (99.2) 22 (100) 205 (98.6) 96 (99.0)
Meropenem 241 (100) 362 (98.4)* 509 (97.7)* 582 (100) 2.800 (100)* 968 (99.7)*
Minocycline 50 (58.8)* 58 (69.0) 47 (67.1) 115 (77.2)* 393 (71.7) 115 (71.4)
Nitrofurantoin 389 (60.2)* 584 (74.8)* 660 (67.7)* 1.119 (86.2)* 5.010 (86.8)* 1.515 (81.7)*
Norfloxacin 400 (98.0) 363 (80.6)* 338 (65.6)* 733 (98.4) 2.664 (94.7)* 712 (79.3)*
Oxacillin 5 (29.4) 16 (39.0)* 43 (51.8) 7 (31.8) 67 (18.6)* 21 (37.5)
Penicillin G 23 (54.8) 38 (44.2)* 89 (47.1) 19 (49.6) 112 (23.9)* 95 (57.6)
Piperacillin/tazobactam 131 (97.8) 184 (84.4)* 258 (81.9)* 306 (96.5) 1.326 (96.4)* 503 (93.8)*
Polymyxin B 2 (100) 15 (100) 23 (100) 13 (100) 4 (100) 11 (100)
Quinupristin/dalfopristin 3 (50.0) 11 (68.8) 17 (56.7) 1 (33.3) 28 (93.3) 10 (45.5)
Rifampin 17 (100) 35 (85.4)* 78 (94.0) 22 (100) 361 (99.7)* 51 (89.5)
Teicoplanin 16 (100) 27 (100) 59 (89.4) 17 (100) 135 (99.3) 61 (98.4)
Tetracycline 20 (47.6)* 50 (54.9)* 81 (54.4) 45 (71.4)* 350 (66.5)* 78 (48.4)
Ticarcillin 73 (81.1)* 86 (78.9)* 82 (73.2)* 141 (91.0)* 520 (93.4)* 162 (89.5)*
Tigecycline – 3 (75.0) 2 (100) 1 (100) 4 (80.0) 3 (100)
Tobramycin 85 (100) 83 (98.8) 71 (98.6) 147 (98.7) 547 (99.5) 159 (98.8)
Trimethoprim/sulfamethoxazole 415 (65.5) 485 (63.0)* 564 (59.2)* 807 (62.4) 4.007 (70.6)* 1.176 (65.1)*
Vancomycin 43 (100) 93 (98.9) 190 (94.1)* 43 (100) 496 (100) 170 (98.8)*
Note: * p < 0.05 compared between gender within each stratum of age indicated (Pearson uncorrected chi-square test or Fisher’s exact test when values ≤ 5).
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nitrofurantoin, and in men, for many of the antibiotics that were tested, 
with the exception of TMP/SMX20. KIFFER et al.19 demonstrated a 
temporal trend of a decreased susceptibility to quinolones from 2000 to 
2003 including ciprofloxacin, norfloxacin, tetracycline, and nalidixic acid 
(p < 0.0001). An earlier study, that was conducted two decades ago in 
Salvador, Northeastern Brazil, showed a reported resistance to norfloxacin 
that reached 9.1% and to ciprofloxacin of 16.5%21.
The study by DIAS et al.11 evaluated the temporal trend of resistance 
among ESBL-producing bacteria and showed a peak of occurrence 
in 2005 (2000-2009) for all antibiotics close to 80% (amikacin, 
ciprofloxacin, gentamicin, nitrofurantoin, TMP/SMX and imipenem) 
and a second peak in 2008 (ciprofloxacin and TMP/SMX were close to 
80% and nitrofurantoin was close to 40%).
The susceptibility of E. coli in 10 Brazilian studies of community-
acquired UTIs showed that only TMP/SMX, cephalothin and 
norfloxacin presented < 80% susceptibility1,2,4,9,10,11,19,20,25,26. In addition to 
nitrofurantoin, to which P. mirabilis presents intrinsic resistance, TMP/
SMX and cephalothin were not good options for treatment of UTIs. 
According to other studies in Brazil, K. pneumoniae retains relative 
susceptibility to fluoroquinolones, as shown in this study, and only 
TMP/SMX and nitrofurantoin were not good options for treatment of 
UTIs. The profile found in the literature for E. aerogenes is similar to 
that found in our study, although the literature data indicate a decreased 
susceptibility to TMP/SMX9,11,19.
Except for lower levels of susceptibility to tetracycline and 
ciprofloxacin, the data regarding E. faecalis from this study resembles that 
found in the study by KIFFER et al.19. Data regarding S. saprophyticus 
demonstrated distinct profiles of susceptibility, and are similar to the 
data found in this study. Finally, there is a notable discrepancy between 
the data regarding the susceptibility of P. aeruginosa in this study and 
that of KIFFER et al.19, the latter being characterized by bacteria with 
more resistance.
A preliminary conclusion of the risk factors could indicate a 
predominance of E. coli in young women and a predominance of other 
more resistant isolates, particularly of Proteus spp. in men, which, 
according to literature, are most affected by urinary infections when 
they develop benign prostatic hyperplasia (BPH), even though the odds 
ratio is statistically significant for patients younger than 6514,15. Data 
from a higher incidence of resistance in elderly men are corroborated 
by three other Brazilian studies19,20,25. ROCHA et al.25 also demonstrate 
a statistically significant difference of the frequency of bacteria between 
men and women. They found a predominance of Enterococcus spp., 
Enterobacter spp. and Pseudomonas spp., but not Proteus spp. in men 
and a predominance of S. saprophyticus and E. coli in women. The same 
study also demonstrated a highly statistically significant susceptibility 
to antibiotics by E. coli and others, which corroborates the data from 
this study.
The favorable resistance profile of E. coli results in an expanded 
list of oral therapeutic options for cystitis treatment in young women, 
including pregnant women, such as fluoroquinolones for not pregnant 
patients, and cephalexin, cefuroxime axetil and amoxicillin/clavulanate 
for pregnant patients. However, a policy of sparing fluoroquinolones in 
such cases is urgently needed. Although it was previously a good option 
for young women, nitrofurantoin had low levels of susceptibility by the 
bacteria that were frequently isolated, such as Proteus spp. (intrinsically 
resistant), Klebsiella spp., Enterobacter spp. and Pseudomonas spp., 
as well as M. morganii and S. marcescens (both intrinsically resistant).
Therefore, the biggest problem with making recommendations for 
empiric antibiotics according to this casuist is men and the elderly. 
P. mirabilis, a urease-producing bacteria that is capable of causing 
struvite urolithiasis and was the second most frequent isolate, presents 
intrinsic resistance to several antibiotics, such as cefazolin, tigecycline, 
polymyxins and nitrofurantoin. Therefore, any empirical recommendation 
for men and elderly people, cannot dispense with fluoroquinolones or a 
reassessment based on early urine cultures.
For complicated infections and pyelonephritis, fluoroquinolones, 
which have renal penetration, such as ciprofloxacin, moxifloxacin 
and levofloxacin (although the latter two are reserved for respiratory 
infections because of their expanded spectrum for Gram-positive bacteria 
and atypical bacteria) are also good choices, although third and fourth 
generation cephalosporins, as well as aminoglycosides, are a second 
option and are preferred in cases of severe sepsis and septic shock. 
Amoxicillin/clavulanate is a good oral treatment option, especially after 
a loading dose of extended-spectrum cephalosporins or aminoglycosides.
Fosfomycin, although not evaluated by the antibiograms in this 
study, had a good susceptibility profile in a small Brazilian study (97.0% 
of susceptibility, n = 118)10 and is an option for multidrug-resistant 
infections, especially for ESBL- and carbapenemase-producing bacteria.
An elegant study from the viewpoint of mathematical modeling in 
the city of São Paulo, Brazil, by KIFFER et al.18 in 2002, demonstrated 
the correlation between the probability of resistance of strains of E. coli 
in urine and the “density the ciprofloxacin usage for the previous three 
months” (defined as D_DDDA), p = 0.023. Additionally, ciprofloxacin 
D_DDDA was found to be related to clusters18: the western region of 
São Paulo was deemed a hot spot for the use of ciprofloxacin (average 
probability of 0.8808). This study is an elegant demonstration of how 
the indiscriminate use of ciprofloxacin against uropathogens may result 
in the loss of a medication to treat a broad spectrum of uropathogens. 
Furthermore, taking into account that approximately 30% to 45% of 
ciprofloxacin ingested is excreted in a non-metabolized form in the urine, 
widespread use can have environmental consequences due to presence 
of the antibiotic in the sewage and exposure of Enterobacteriaceae to the 
antibiotic in that environment. This finding only reinforces the urgent 
need, based on studies, for an efficient policy of reducing the use of 
fluoroquinolones and broader-spectrum antibiotics.
A recent study in the United States17 showed a higher risk of 
levofloxacin-resistant E. coli related to previous use of this antibiotic 
(adjusted OR = 7.6, 9% CI: 2.1-27.5, p = 0.002) and previous 
hospitalization (OR = 2.0, 95% CI: 1.0-3.9, p = 0.04) as well as a 
statistically significant risk to resistance to other antibiotics in isolates 
resistant to this fluoroquinolone. Another interesting finding was 
increased rates of resistance to TMP/SMX despite a 50% decrease in 
the selective pressure, which is most likely due to multidrug resistance 
plasmids or multidrug efflux pumps.
This study has several limitations, even though it has the merit of 
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being one of the few and largest of its type in Brazil: there is one small 
study of the antimicrobial susceptibility profile according to clinical 
presentation. In our analysis, we do not separate nosocomial infections 
from those acquired in the community. The samples were collected not 
only from midstream but also by other techniques, such as indwelling 
catheter, which can increase the chance of isolating hospital germs. 
Despite this, our resistance rates are similar to studies that included 
only community isolates. Our analysis was based on retrospective data 
and focused on microbiological aspects. Reproducibility problems can 
arise due to differences in interpretation of the minimum inhibitory 
concentration (MIC) between CLSI and EUCAST (European Committee 
on Antimicrobial Susceptibility Testing) documents.
Studies assessing other demographic, clinical, radiological and 
laboratory risk factors (including multivariate analysis to control for 
confounding factors) for infections by germs other than E. coli, such 
as Proteus spp., Enterobacter spp., Pseudomonas spp. and Klebsiella 
spp., are urgently needed, to make treatment recommendations that can 
save broad-spectrum drugs, such as fluoroquinolones, and third and 
fourth generations of cephalosporins, carbapenems, fosfomycin and 
aminoglycosides.
CONCLUSIONS
The most favorable scenario is the treatment of E. coli. TMP/SMX 
and nalidixic acid were only two whose resistance exceeds the threshold 
of 20%, which contraindicates their use according to the guidelines, in 
our study. The rise of resistance to fluoroquinolones is concerning and 
averaged 12%. Furthermore, the 20% threshold resistance was exceeded 
by norfloxacin in the overall analysis, mainly at the expense of bacteria 
other than E. coli. In this study, a high frequency of community-acquired 
ESBL bacteria was found, which is greater than that found in a study in 
Brazil, but within the range described in the literature. Most isolates were 
observed in the elderly. As in other studies, the main problem of resistance 
was noted in men and in the elderly, which limits most conservative 
treatment recommendations that save broad-spectrum antibiotics such 
as fluoroquinolones, aminoglycosides and third and fourth generations 
cephalosporins. Well-controlled prospective studies that evaluate the risk 
factors for UTIs by bacteria other than E. coli and resistance in Brazil 
are greatly needed.
RESUMO
Suscetibilidade a antibióticos em infecções de trato urinário em 
um hospital secundário, 2005-2006 e 2010-2011, em São Paulo, 
Brasil: dados de 11.943 uroculturas
Introdução: A infecção do trato urinário (ITU) tem alta incidência e 
recorrência, e o tratamento é empírico na maioria dos casos. Objetivos: 
O objetivo deste estudo foi analisar as culturas de urina realizadas em um 
hospital secundário, durante dois períodos: 2005-2006 e 2010-2011, para 
estimar a resistência microbiana. Pacientes e métodos: Foram analisadas 
11.943 culturas aeróbicas de urina de acordo com um conjunto de dados 
demográficos básicos e susceptibilidade aos antibióticos, obedecendo às 
normas do Clinical and Laboratory Standards Institute (CLSI) para Vitek 
1 e 2. Resultados: A maioria dos participantes era adulta e jovem atendida 
no Serviço de Emergência. E. coli foi a mais freqüente (70,2%) entre as 
75 espécies isoladas. Resistência de todos os isolados foi ≥ 20% para 
sulfametoxazol/trimetoprim (SMX/TMP), norfloxacina, nitrofurantoína, 
cefazolina e ácido nalidíxico, apesar de E. coli ter sido mais suscetível 
(resistência ≥ 20% apenas para SMX/TMP e ácido nalidíxico) entre todos 
os isolados, levando em conta a porcentagem de resistência e o número 
de antibióticos testados. Resistência às fluoroquinolonas foi de 12%. 
Fatores de risco para E. coli: sexo feminino e idade < 65 anos. Homens 
e pacientes com mais de 65 anos apresentaram isolados mais resistentes. 
Beta-lactamases de espectro estendido (ESBL) foram identificadas em 
173 de 5.722 isolados Gram-negativos (3,0%), 2010-2011. Conclusões: 
E. coli foi o isolado mais sensível a antibióticos. Houve uma evolução 
significativa da resistência antimicrobiana entre os dois períodos. Foi 
preocupante o aumento da resistência às fluoroquinolonas.
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